Table 2.

Univariate analysis of PFS and OS.

Characteristics	PFS		OS
	HR (95% CI)	P-value	HR (95% CI)	P-value
Gender (Female/Male)	0.943 (0.655-1.357)	0.753	0.694 (0.303-1.590)	0.388
Age (<60/≥60, years)	0.960 (0.673-1.370)	0.822	0.827 (0.365-1.873)	0.650
ECOG PS (<2/≥2)	13.103 (7.924-21.667)	<0.001*	3.334 (0.375-29.662)	0.280
Smoking history	7.468 (4.782-11.662)	<0.001*	11.021 (1.754-69.242)	0.010*
EGFR status (Wild/Mutation/Unknown)	1.054 (0.840-1.321)	0.651	0.870 (0.546-1.387)	0.558
No. of metastases (0/≤2/≥3)	1.395 (1.103-1.764)	0.005*	1.125 (0.669-1.891)	0.657
Pre-radiotherapy	1.039 (0.726-1.488)	0.834	0.741 (0.336-1.634)	0.457
Pathology (AD/SCC/Others)	1.049 (0.827-1.332)	0.692	0.664 (0.314-1.404)	0.284
Apatinib dose (=500/>500, mg/d)	1.309 (0.828-2.069)	0.250	2.923 (1.006-8.492)	0.049*
Line of Apatinib (Second line/Further line)	0.969 (0.504-1.864)	0.924	0.252 (0.067-0.949)	0.042*
TNM stage (III/IV)	2.858 (1.939-4.211)	<0.001*	1.427 (0.466-4.369)	0.534
Short-term efficacy (PR/SD/PD)	3.223 (2.277-4.562)	<0.001*	1.162 (0.454-2.972)	0.754
Hypertension	0.290 (0.190-0.442)	<0.001*	0.635 (0.175-2.310)	0.491
Proteinuria	1.230 (0.815-1.855)	0.325	1.310 (0.475-3.614)	0.602
HFS	0.933 (0.617-1.411)	0.743	1.580 (0.669-3.730)	0.297

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AD, adenocarcinoma; SCC, squamous cell carcinoma; TNM, tumor, node, and metastases; PR, partial response; SD, stable disease; PD, progressive disease; HFS, hand-foot syndrome.

*Statistically significant values, P <0.05.